JPH01207232A - Preventive and therapeutic agent for hangover - Google Patents
Preventive and therapeutic agent for hangoverInfo
- Publication number
- JPH01207232A JPH01207232A JP3179588A JP3179588A JPH01207232A JP H01207232 A JPH01207232 A JP H01207232A JP 3179588 A JP3179588 A JP 3179588A JP 3179588 A JP3179588 A JP 3179588A JP H01207232 A JPH01207232 A JP H01207232A
- Authority
- JP
- Japan
- Prior art keywords
- hangover
- alanine
- drinking
- alcohol
- preventive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、二日酔の予防および治療剤に関し、より詳細
には、人工甘味料およびL−アラニンを主成分とする二
日酔予防治療剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to a preventive and therapeutic agent for hangover, and more particularly, to a hangover preventive treatment containing an artificial sweetener and L-alanine as main ingredients. Regarding drugs.
古来、「酒は百薬の長」等と言われ、人類の長い歴史の
中で、各種のアルコール性飲料が嗜まれてきた。反面、
度が過ぎれば百害あって一利もないことは経験の教える
ところである。Since ancient times, it has been said that ``alcohol is the greatest medicine,'' and throughout the long history of mankind, various alcoholic beverages have been enjoyed. On the other hand,
Experience has taught us that if taken too far, it can cause harm and no benefit.
遠い時代からアルコール性飲料の弊害をなくすため、法
律的に禁酒の規制を加えたり、また宗教的、教育的に飲
酒が悪習であると伝達する等の努力が行われてきた。し
かしながら、脈脈と続けてきた飲酒の習慣をなくすこと
は極めて難しく、その困難さは、飲酒の経験者の多くが
体験してきたことである。Efforts have been made since ancient times to eliminate the harmful effects of alcoholic beverages, such as adding legal prohibitions against drinking, and religiously and educationally promoting the idea that drinking is a bad habit. However, it is extremely difficult to break the habit of drinking that has continued for a long time, and many people who have experienced drinking have experienced this difficulty.
飲酒による酔いは、個人差があるものの、−Sには酔後
頭痛、二日酔い等の症状を呈し、多量の飲酒を続けると
肝臓の機能が妨げられ、引いてはアルコール性中毒に到
るとされている。このような背景にあって、アルコール
性肝臓障害等については、医学的にも研究が行なわれ、
様々の医薬や治療方法が開発され実用化されている。Although the degree of intoxication caused by drinking alcohol varies from person to person, -S exhibits symptoms such as post-intoxication headaches and hangovers, and continued drinking in large quantities can impair liver function, leading to alcohol poisoning. ing. Against this background, medical research is being conducted on alcoholic liver damage, etc.
Various medicines and treatment methods have been developed and put into practical use.
しかし、多くの人々が飲酒により体験する、いわゆる「
二日酔」の現象は、嘔吐、頭痛、食欲不振等を引き起こ
し、極めて不快な状況を形成し、愛飲家をして、二度と
飲酒をするまいとの一時的決断を促すものである。しか
し、このような決心にかかわらず、いつの間にか自ら再
び飲酒の習慣に陥ってしまったり、また社交上必要に迫
られて飲酒の機会を持たざるを得すに飲酒し、「二日酔
」を繰り返してしまうことがある。このような場合の応
急策として、タマゴ酒、ムカイ酒等古くから伝えられて
いる方法があるが、どれをとっても個人差があり、二日
酔の防止または治療には有効な方策はないといえるのが
現状である。However, many people experience the so-called "
The phenomenon of a hangover causes vomiting, headache, loss of appetite, etc., creating an extremely unpleasant situation that prompts drinkers to temporarily decide not to drink alcohol again. However, regardless of this determination, some people find themselves falling back into the habit of drinking again, or drinking when forced to drink due to social necessity, resulting in a ``hangover.'' Sometimes I end up repeating myself. As an emergency measure in such cases, there are methods that have been passed down for a long time, such as egg sake and mukai sake, but each method differs from person to person, and it can be said that there is no effective method for preventing or treating hangovers. is the current situation.
(問題点を解決するための手段]
本発明者は、前記のような二日酔を有効適切に予防また
は治療することを渇望し、特に、飲酒の機会は、時を選
ばないことがあるので、このようなときに気軽に服用可
能で、予防・治療効果の大きい予防・治療剤を見出すこ
とを鋭意検討した。(Means for Solving the Problems) The present inventors desire to effectively and appropriately prevent or treat hangovers as described above, and in particular, since the opportunity to drink alcohol may occur at any time, We have conducted extensive research into finding preventive and therapeutic agents that can be easily taken in such cases and have great preventive and therapeutic effects.
その結果、L−アラニンと人工甘味料を含有し混合して
なる予防・治療剤がこれらの要望を充分に満たすもので
あることを見出し、本願発明を完成した。As a result, they discovered that a preventive/therapeutic agent containing and mixing L-alanine and an artificial sweetener satisfies these needs, and completed the present invention.
すなわち、本願発明は、し−アラニンと人工甘味料を主
成分とし、L−アラニンの特有のアミノ酸呈味質を改善
し、味覚も好ましく手軽に服用可能な予防・治療剤を完
成するに至ったものであり、アラニン及び人工甘味料を
主成分とすることを特徴とするものである。That is, the present invention has completed a prophylactic/therapeutic agent that uses shi-alanine and an artificial sweetener as main ingredients, improves the unique amino acid taste quality of L-alanine, has a pleasant taste, and can be easily taken. It is characterized by containing alanine and artificial sweeteners as main ingredients.
本願発明で使用するL−アラニンは、全てのタンパク質
にも含まれているアミノ酸であって、毒性がないことが
確認されている物質である。L-alanine used in the present invention is an amino acid that is also contained in all proteins, and is a substance that has been confirmed to be non-toxic.
このL−アラニンが二日酔に有効であること、また、オ
ルニチンとの混合使用でアルコール性肝臓障害に有効で
あることは既に知られている。It is already known that this L-alanine is effective for hangovers, and that it is effective for alcoholic liver damage when used in combination with ornithine.
しかし、L−アラニンは比較的甘味はあるもののまろや
かさに欠け、さらに他のアミノ酸を混ぜて使用しても、
アミノ酸特有の苦み等を呈するので、単独で服用するに
は好ましくない。However, although L-alanine has a relatively sweet taste, it lacks mellowness, and even when mixed with other amino acids,
Since it exhibits the bitterness characteristic of amino acids, it is not preferable to take it alone.
そのため、例えば、L−アラニンを含むドリンク剤とし
ても、服用の容易さや手軽さ等が十分に解決できず、携
帯して必要なとき服用できるという手軽さはないは。Therefore, for example, even a drink containing L-alanine does not have sufficient ease and convenience to take, and is not convenient enough to be carried around and taken when needed.
このように、本願発明で使用するし一アラニンの二す酔
予防または治療剤としての、味覚および服用面での改善
は行われていない。As described above, the monoalanine used in the present invention as an agent for preventing or treating hangover has not been improved in terms of taste and administration.
本発明で使用するし一アラニンは人工甘味料を配合する
ことにより、L−アラニン単独の場合に比べ、呈味性が
大巾に改善され、通常、飲みやすい味を発現することが
できる。By incorporating an artificial sweetener into the L-alanine used in the present invention, the taste properties are greatly improved compared to when L-alanine alone is used, and it is usually possible to develop a taste that is easy to drink.
L−アラニンに対する人工甘味料の使用量は、L−アラ
ニンの呈味性が改善しうる量であれば、特に限定されな
いが、−Cに、効果と味覚面から、し−アラニンに対し
て 0.1〜5.0重量%が多用される。The amount of artificial sweetener to be used for L-alanine is not particularly limited as long as it can improve the taste of L-alanine. .1 to 5.0% by weight is often used.
使用する人工甘味料として、サッカリン、ジペプチド系
甘味料、その他各種の甘味料が使用できるが、α−し一
アスパルチルーL−フェニルアラニンメチルエステル(
以下、アスパルテームと略記する)が特に好ましく用い
られる。このアスパルテームであれば、その使用量に対
する味覚改善効果が極めて大きく、予防・治療剤として
の服用の容易さの点で優れたものを得ることができる。As the artificial sweetener to be used, saccharin, dipeptide sweeteners, and various other sweeteners can be used.
Particularly preferably used is aspartame (hereinafter abbreviated as aspartame). This aspartame has an extremely large effect on taste improvement depending on the amount used, and can be used as a prophylactic/therapeutic agent that is easy to take.
例えば、L−アラニンとアスパルテームとのン昆合物で
あれば、し−アラニンに対して0.5〜1.0重量%の
アスパルテームを混合した組成物で、し−アラニンの特
有の味覚はまろやかなものに改善され、飲酒前に体重1
kg当たり僅か0.5〜to+mg程度を服用すれば、
可なりの深酒であっても二日酔を予防し、また飲酒後、
同様に服用することによって二日酔を治療できる。For example, in the case of a mixture of L-alanine and aspartame, the composition is a mixture of 0.5 to 1.0% by weight of aspartame to L-alanine, and the characteristic taste of L-alanine is mellow. The weight has improved by 1 lb before drinking alcohol.
If you take only 0.5~to+mg per kg,
Prevents hangovers even when drinking heavily, and after drinking,
You can also treat hangovers by taking it in the same way.
本発明の二日酔予防治療剤は、通常、体重1 kg当た
り0.1〜100■の割合で服用される。The hangover prevention and treatment agent of the present invention is usually taken at a rate of 0.1 to 100 ml per 1 kg of body weight.
本発明の二日酔予防治療剤は、し−アラニンにアスパル
テームような人工甘味料を直接配合して、服用容易な形
状の剤とすることができるが、他の目的を兼ねさせて、
オルニチン、トリプトファン等の他のアミノ酸、増量剤
等のその他の成分を併用することも、本発明の態様に含
まれる。The hangover prevention and treatment agent of the present invention can be made into an easy-to-take form by directly blending alanine with an artificial sweetener such as aspartame, but it can also be used for other purposes.
The combined use of other amino acids such as ornithine, tryptophan, and other components such as fillers is also included in the embodiment of the present invention.
また、粉末状または錠剤等の各種形状でも使用できるが
、特にこれらの形状に限定されるものではない。しかし
、これらの形状はその呈味性で顕著であり、服用も容易
である点で好ましい。Further, it can be used in various forms such as powder or tablet, but is not particularly limited to these forms. However, these shapes are preferable because they have a distinct taste and are easy to take.
〔発明の効果]
本発明に係わる二日酔予防治療剤は、飲酒の前、飲酒中
または飲酒後に服用することにより、殆ど個人差もなし
に、その効果を期待することができる。[Effects of the Invention] By taking the hangover prevention and treatment agent according to the present invention before, during, or after drinking alcohol, its effects can be expected with almost no individual difference.
実施例−1
L−アラニン100gとアスパルテーム1gとを混合し
、充分に混ぜ合わせ、二日酔予防治療剤を調製した。Example-1 100 g of L-alanine and 1 g of aspartame were mixed and mixed thoroughly to prepare a hangover prevention and treatment agent.
この治療剤を用い、飲酒の習慣をもち、かつ二日酔の経
験のある成年男子18名を対象にし、飲酒30分前に1
人当たり各人の体重1kg当たり3+ogを服用させた
後、各人が過去において二日酔を経験したときの酒量、
種類(ワイン、日本酒、洋酒等)にほぼ合せて飲酒して
貰い、治療剤の服用し易さ、および酩酊の状態と二日酔
い症状の発生状況等を調べた。Using this treatment, 18 adult men who had a habit of drinking alcohol and had experienced hangovers were given one dose of alcoholic beverages 30 minutes before drinking alcohol.
The amount of alcohol consumed when each person experienced a hangover in the past after taking 3+ og per kg of body weight per person,
The participants were asked to drink approximately different types of alcohol (wine, Japanese sake, Western liquor, etc.), and the ease with which they could take therapeutic drugs, as well as their state of intoxication and the occurrence of hangover symptoms, were investigated.
その結果、すべての被験者において、飲みやすく、かつ
飲酒後に二日酔の症状は全くなかった。As a result, all subjects found it easy to drink and had no hangover symptoms after drinking.
かつ爽快であると感想を得た。I got the impression that it was also refreshing.
この結果から、L−アラニンの呈味質は大幅に改善され
、二日酔の予防効果が顕著なものであることが明らかと
なった。These results revealed that the taste quality of L-alanine was significantly improved, and that it had a remarkable hangover preventive effect.
実施例−2
実施例−1と同しくの二日酔予防治療剤を調製した。実
施例−1と別の成人男子15人からなる飲酒家のグルー
プを選び、上記治療剤を飲酒中に服用したこと以外は実
施例1と同様にして試験を行なった。飲酒後の二日酔い
の発生状況を調べたところ、二日酔の症状は全くなかっ
た。この結果から、既に飲酒中に服用しても、二日酔を
予防する効果が極めて優れていることが確認された。Example-2 The same hangover prevention and treatment agent as in Example-1 was prepared. A group of alcohol drinkers consisting of 15 adult males other than those in Example 1 was selected, and a test was conducted in the same manner as in Example 1, except that the therapeutic agent was taken while drinking alcohol. When we investigated the occurrence of hangovers after drinking alcohol, we found that there were no hangover symptoms at all. These results confirm that the drug is extremely effective in preventing hangovers even when taken while already drinking alcohol.
また、飲酒中でも手軽に服用可能であり、飲酒中であっ
てもその呈する味に意味はないとの感想を得た。In addition, it can be easily taken while drinking alcohol, and the impression was received that the taste it produces has no meaning even when drinking alcohol.
実施例−3
実施例=1と同しくの二日酔予防治療剤を調製した。別
の飲酒家のグループ成人男子30人を選び、これを15
人づつ二つのグループに分け、実施例1と同様に過去の
二日酔を起こしたに足りるに充分な量を飲酒後、一つの
グループは10分してから上記治療剤を服用させ、他の
グループには服用させなかった。Example 3 The same hangover prevention and treatment agent as in Example 1 was prepared. Select another group of 30 adult men who drink alcohol, and divide this into 15
Divide each person into two groups, and as in Example 1, after drinking enough to cause a previous hangover, one group was given the therapeutic agent 10 minutes later, and the other group The group was not given doses.
その結果、服用しなかったグループでは4人が嘔吐に到
る二日酔いの状態に至り、8人が重い頭痛に見舞われ、
3人が軽い二日酔いの状態になった。しかし、服用した
グループでは殆ど二日酔いの状態に至らず、僅か3人が
軽い頭痛の症状を呈した程度であった。この治療剤の服
用を嫌がる人は一人もいなかった。As a result, in the group that did not take the drug, four people experienced hangovers that led to vomiting, and eight people suffered from severe headaches.
All three of us had slight hangovers. However, almost no one in the group who took the drug experienced a hangover, and only three people had mild headaches. Not a single person was reluctant to take this treatment.
この結果から、飲酒直後の服用によっても二日酔いの予
防効果があることが確認された。These results confirmed that taking the drug immediately after drinking alcohol has a hangover preventive effect.
実施例−4
二日酔を訴える成人男子12名に、実施例−1と同様に
調製した二日酔予防治療剤を一人当たり体重Ikg当た
り5■ずつ服用させた。Example 4 Twelve male adult men complaining of hangovers were given a hangover prevention and treatment agent prepared in the same manner as in Example 1, at a dose of 5 ml per Ikg of body weight.
服用時に、いずれの被験者も嘔吐を起こす様なことはな
(、各人とも容易に服用し、1〜3時間後には、二日酔
特有の不快感が消滅したことを報告した。None of the subjects experienced vomiting when taking the drug (all subjects took the drug easily, and reported that the discomfort characteristic of a hangover disappeared 1 to 3 hours later).
特許出願人 三井東圧化学株式会社Patent applicant: Mitsui Toatsu Chemical Co., Ltd.
Claims (1)
酔予防治療剤。 2、L−アラニンおよびα−L−アスパルチル−L−フ
ェニルアラニンを主成分とする二日酔予防治療剤。[Scope of Claims] 1. A hangover prevention and treatment agent containing L-alanine and an artificial sweetener as main ingredients. 2. A hangover prevention and treatment agent containing L-alanine and α-L-aspartyl-L-phenylalanine as main ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63031795A JPH0832627B2 (en) | 1988-02-16 | 1988-02-16 | Hangover preventive treatment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP63031795A JPH0832627B2 (en) | 1988-02-16 | 1988-02-16 | Hangover preventive treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH01207232A true JPH01207232A (en) | 1989-08-21 |
| JPH0832627B2 JPH0832627B2 (en) | 1996-03-29 |
Family
ID=12341002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63031795A Expired - Lifetime JPH0832627B2 (en) | 1988-02-16 | 1988-02-16 | Hangover preventive treatment |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0832627B2 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1007099A5 (en) * | 1993-11-22 | 1995-03-14 | Messadek Jallal | Drug activity aspartame. |
| WO1995016457A1 (en) * | 1993-12-16 | 1995-06-22 | Edmond Creppy | Aspartame for use as a therapeutically active substance |
| WO1997000692A1 (en) * | 1995-06-23 | 1997-01-09 | Oklahoma Medical Research Foundation | ANALGESIC USE OF N-L-α-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER |
| JP2001081036A (en) * | 1999-09-09 | 2001-03-27 | Nichiro Corp | Composition for preventing and improving sickness and hangover and method for producing the same |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60241871A (en) * | 1984-05-16 | 1985-11-30 | Ajinomoto Co Inc | Production of disintegrable tablet containing aspartame |
| JPS61134313A (en) * | 1984-12-03 | 1986-06-21 | Suntory Ltd | Agent for suppressing toxicity of aldehyde |
| JPS61212256A (en) * | 1985-03-15 | 1986-09-20 | Ajinomoto General Food Kk | Sweetener composition having low calorific value |
| JPS61268152A (en) * | 1985-05-22 | 1986-11-27 | Nippon Baruku Yakuhin Kk | Artificial sweetener |
| JPS62232362A (en) * | 1986-04-01 | 1987-10-12 | Ajinomoto Co Inc | Carbonated beverage |
-
1988
- 1988-02-16 JP JP63031795A patent/JPH0832627B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60241871A (en) * | 1984-05-16 | 1985-11-30 | Ajinomoto Co Inc | Production of disintegrable tablet containing aspartame |
| JPS61134313A (en) * | 1984-12-03 | 1986-06-21 | Suntory Ltd | Agent for suppressing toxicity of aldehyde |
| JPS61212256A (en) * | 1985-03-15 | 1986-09-20 | Ajinomoto General Food Kk | Sweetener composition having low calorific value |
| JPS61268152A (en) * | 1985-05-22 | 1986-11-27 | Nippon Baruku Yakuhin Kk | Artificial sweetener |
| JPS62232362A (en) * | 1986-04-01 | 1987-10-12 | Ajinomoto Co Inc | Carbonated beverage |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1007099A5 (en) * | 1993-11-22 | 1995-03-14 | Messadek Jallal | Drug activity aspartame. |
| WO1995014486A1 (en) * | 1993-11-22 | 1995-06-01 | Messadek, Jallal | Medicinal activity of aspartame |
| WO1995016457A1 (en) * | 1993-12-16 | 1995-06-22 | Edmond Creppy | Aspartame for use as a therapeutically active substance |
| FR2714064A1 (en) * | 1993-12-16 | 1995-06-23 | Creppy Edmond | Aspartame for its application as a therapeutically active substance. |
| US5496856A (en) * | 1993-12-16 | 1996-03-05 | Creppy; Edmond | Aspartame for its application as a therapeutically active substance |
| WO1997000692A1 (en) * | 1995-06-23 | 1997-01-09 | Oklahoma Medical Research Foundation | ANALGESIC USE OF N-L-α-ASPARTYL-L-PHENYLALANINE 1-METHYL ESTER |
| US5654334A (en) * | 1995-06-23 | 1997-08-05 | Oklahoma Medical Research Foundation | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester |
| US5998473A (en) * | 1995-06-23 | 1999-12-07 | Oklahoma Medical Research Foundation | Analgesic use of N-L-α-aspartyl-L-phenylalanine 1-methyl ester derivatives |
| JP2001081036A (en) * | 1999-09-09 | 2001-03-27 | Nichiro Corp | Composition for preventing and improving sickness and hangover and method for producing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0832627B2 (en) | 1996-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0983726B1 (en) | Amino acid-trehalose composition | |
| US5286748A (en) | General method of shortening the duration of common colds by application of medicaments to tissues of oral cavity | |
| JPH0952835A (en) | Peroral medicine constitution | |
| CA2242646C (en) | Amino acid composition | |
| ES2539414T3 (en) | Liquid formulation for deferiprone with appetizing flavor | |
| JP2002512978A (en) | Nicotine-containing solution | |
| KR20010031499A (en) | Medicinal compositions with relieved bitterness, etc. | |
| EP0396634A1 (en) | METHOD FOR TREATING XEROSTOMIA USING CHEWING GUM. | |
| EA001878B1 (en) | Method for treatment of bacterial infection in children | |
| JPH04211614A (en) | Method and composition for developing ability | |
| WO2004050025A3 (en) | Combination of ibuprofen and oxycodone for acute pain relief | |
| CN1658898B (en) | Orodispersible pharmaceutical composition comprising perindopril | |
| JPH01207232A (en) | Preventive and therapeutic agent for hangover | |
| US6506552B2 (en) | Amino acid-trehalose composition | |
| US4985257A (en) | Hemorrhoidal treatment and composition | |
| JP2002193839A (en) | Cocoa pharmaceutical preparation | |
| ES2618930T5 (en) | Composition comprising diamine oxidase for the prevention of hangover symptoms | |
| JP2000273051A (en) | Liquid preparation whose bitter taste is masked | |
| JPH08277221A (en) | Alcohol absorption inhibitor | |
| EP0715850B1 (en) | Use of proline and/or derivatives as an antihepatitis agent | |
| JP2001524502A (en) | Rejuvenation formulation | |
| JPH06336432A (en) | Adrenaline and noradrenaline secretagogue composition | |
| RU2120280C1 (en) | Homeopathic agent "atsenamet" for treatment of alcohol addiction | |
| JP2891738B2 (en) | Alcohol absorption inhibitor | |
| JPH01238538A (en) | Peptic and digestive agent |